CDKN2C and cancer: Ten cancers had an upregulated CDKN2C expression, namely cholangiocarcinoma (CHOL), esophageal carcinoma (ESCA), glioblastoma multiforme (GBM), head and neck squamous cell carcinoma (HNSCC), kidney renal clear cell carcinoma (KIRC), LIHC, LUAD, lung squamous cell carcinoma (LUSC), stomach adenocarcinoma (STAD), and THCA (p < 0.05; Fig. 5A).